224 related articles for article (PubMed ID: 24378129)
1. [Immunogenicity and safety of a booster dose of inactivated polio vaccine].
Li XM; Zhang ZJ; Wang HH; Liu F; Zhang LW; Chu P; Xu Y; Zhang HR; Li J; Liu DL; Lu L
Zhonghua Yu Fang Yi Xue Za Zhi; 2013 Oct; 47(10):905-9. PubMed ID: 24378129
[TBL] [Abstract][Full Text] [Related]
2. Primary and booster vaccination with an inactivated poliovirus vaccine (IPV) is immunogenic and well-tolerated in infants and toddlers in China.
Li R; Li CG; Li Y; Liu Y; Zhao H; Chen X; Kuriyakose S; Van Der Meeren O; Hardt K; Hezareh M; Roy-Ghanta S
Vaccine; 2016 Mar; 34(12):1436-43. PubMed ID: 26873055
[TBL] [Abstract][Full Text] [Related]
3. Safety and immunogenicity of inactivated poliovirus vaccine based on Sabin strains with and without aluminum hydroxide: a phase I trial in healthy adults.
Verdijk P; Rots NY; van Oijen MG; Oberste MS; Boog CJ; Okayasu H; Sutter RW; Bakker WA
Vaccine; 2013 Nov; 31(47):5531-6. PubMed ID: 24063976
[TBL] [Abstract][Full Text] [Related]
4. Diphtheria-tetanus-acellular pertussis and inactivated poliovirus vaccines given separately or combined for booster dosing at 4-6 years of age.
Black S; Friedland LR; Ensor K; Weston WM; Howe B; Klein NP
Pediatr Infect Dis J; 2008 Apr; 27(4):341-6. PubMed ID: 18316985
[TBL] [Abstract][Full Text] [Related]
5. Immunogenicity and safety of a booster dose of diphtheria, tetanus, acellular pertussis and inactivated poliomyelitis vaccine (Tdap-IPV; Repevax) administered concomitantly versus non-concomitantly with an influenza vaccine (Vaxigrip) to adults aged ≥60 years: an open-label, randomised trial.
Zimmermann U; Gavazzi G; Richard P; Eymin C; Soubeyrand B; Baudin M
Vaccine; 2013 Mar; 31(11):1496-502. PubMed ID: 23313654
[TBL] [Abstract][Full Text] [Related]
6. [Study of immunogenicity after primary vaccination by different sequential program of inactivated poliovirus vaccine and oral poliovirus vaccine].
Lu L; Li XM; Liu DL; Zhang HR; Zhang ZJ; Wang HH; Liu F; Ning ZQ; Zhang LW; Chu P; Xie YT; Xu Y; Li J; Pang XH; Deng Y
Zhonghua Yu Fang Yi Xue Za Zhi; 2012 Jun; 46(6):510-3. PubMed ID: 22943896
[TBL] [Abstract][Full Text] [Related]
7. [Comparing the immunogenicity and safety of sequential inoculation of sIPV followed by bOPV (Ⅰ+Ⅲ) in different dosage forms].
Ye H; Huang T; Ying ZF; Li GL; Che YC; Zhao ZM; Wang JF; Yang XL; Shi L; Jiang RJ; Liu XC; Mo ZJ; Li CG; Yang JS
Zhonghua Yu Fang Yi Xue Za Zhi; 2018 Jan; 52(1):43-49. PubMed ID: 29334707
[No Abstract] [Full Text] [Related]
8. One-year post-primary antibody persistence and booster immune response to a fully liquid five-component acellular pertussis, diphtheria, tetanus, inactivated poliomyelitis, Haemophilus influenzae type b conjugate vaccine.
Lin TY; Wang YH; Huang YC; Chiu CH; Lin PY; Chen CJ; Chavand P; Ortiz E
Int J Infect Dis; 2007 Nov; 11(6):488-95. PubMed ID: 17349809
[TBL] [Abstract][Full Text] [Related]
9. Surveillance of immunity acquired from poliovirus immunization including vaccination with the Sabin strain-derived inactivated vaccine.
Hotta C; Ogawa T; Shirasawa H
Hum Vaccin Immunother; 2019; 15(5):1154-1159. PubMed ID: 30676843
[TBL] [Abstract][Full Text] [Related]
10. First-in-human safety and immunogenicity investigations of three adjuvanted reduced dose inactivated poliovirus vaccines (IPV-Al SSI) compared to full dose IPV Vaccine SSI when given as a booster vaccination to adolescents with a history of IPV vaccination at 3, 5, 12months and 5years of age.
Lindgren LM; Tingskov PN; Justesen AH; Nedergaard BS; Olsen KJ; Andreasen LV; Kromann I; Sørensen C; Dietrich J; Thierry-Carstensen B
Vaccine; 2017 Jan; 35(4):596-604. PubMed ID: 28027810
[TBL] [Abstract][Full Text] [Related]
11. Safety and immunogenicity of a DTaP-IPV(Vero) (serum-free) combination vaccine in comparison to DTaP-IPV(Mkc) when administered simultaneously with Haemophilus influenzae type B conjugate vaccine (PRP-T) in children at 2, 3.5, 5 and 16 months of age.
Pietrzyk JJ; Wysocki J; Pejcz J; Galaj A; Majda-Stanislawska E; Käyhty H; Thierry-Carstensen B; Jensen AM
Vaccine; 2008 Sep; 26(41):5296-303. PubMed ID: 18675870
[TBL] [Abstract][Full Text] [Related]
12. Immunogenicity and safety of a DTaP-IPV//PRP-T vaccine (Pentaxim) booster during the second year of life in Thai children primed with an acellular pertussis combined vaccine.
Thisyakorn U; Pancharoen C; Chuenkitmongkol S; Ortiz E
Southeast Asian J Trop Med Public Health; 2009 Mar; 40(2):282-94. PubMed ID: 19323013
[TBL] [Abstract][Full Text] [Related]
13. Immunogenicity and persistence from different 3-dose schedules of live and inactivated polio vaccines in Chinese infants.
Lu L; Li X; Zhang H; Liu D; Zhang Z; Wang H; Liu F; Ning Z; Li J; Pang X
Vaccine; 2015 Aug; 33(36):4653-8. PubMed ID: 25681659
[TBL] [Abstract][Full Text] [Related]
14. Long-term evaluation of mucosal and systemic immunity and protection conferred by different polio booster vaccines.
Xiao Y; Daniell H
Vaccine; 2017 Sep; 35(40):5418-5425. PubMed ID: 28111147
[TBL] [Abstract][Full Text] [Related]
15. Safety and immunogenicity of a primary course and booster dose of a combined diphtheria, tetanus, acellular pertussis, hepatitis B and inactivated poliovirus vaccine.
Meriste S; Lutsar I; Tamm E; Willems P
Scand J Infect Dis; 2006; 38(5):350-6. PubMed ID: 16709537
[TBL] [Abstract][Full Text] [Related]
16. Antibody persistence after primary and booster doses of a pentavalent vaccine against diphtheria, tetanus, acellular pertussis, inactivated poliovirus, haemophilus influenzae type B vaccine among Thai children at 18-19 months of age.
Chotpitayasunondh T; Thisyakorn U; Pancharoen C; Chuenkitmongkol S; Ortiz E
Southeast Asian J Trop Med Public Health; 2012 Mar; 43(2):442-54. PubMed ID: 23082595
[TBL] [Abstract][Full Text] [Related]
17. Immunogenicity, reactogenicity and safety of a 7-valent pneumococcal conjugate vaccine (PCV7) concurrently administered with a DTPa-HBV-IPV/Hib combination vaccine in healthy infants.
Knuf M; Habermehl P; Cimino C; Petersen G; Schmitt HJ
Vaccine; 2006 May; 24(22):4727-36. PubMed ID: 16616973
[TBL] [Abstract][Full Text] [Related]
18. Persistence of protective anti-poliovirus antibody levels in 4-year-old children previously primed with Picovax®, a trivalent, aluminium-adjuvanted reduced dose inactivated polio vaccine.
Sáez-Llorens X; Chan M; DeAntonio R; Petersen T; Olesen C; Jensen JS; Sørensen C; Ekstrand LM; Czort MK; Kristensen HH; Thulstrup N; Christoffersen DB
Vaccine; 2022 Sep; 40(40):5835-5841. PubMed ID: 36064670
[TBL] [Abstract][Full Text] [Related]
19. Immunogenicity and safety of a combined DTaP-IPV vaccine compared with separate DTaP and IPV vaccines when administered as pre-school booster doses with a second dose of MMR vaccine to healthy children aged 4-6 years.
Black S; Friedland LR; Schuind A; Howe B;
Vaccine; 2006 Aug; 24(35-36):6163-71. PubMed ID: 16759769
[TBL] [Abstract][Full Text] [Related]
20. Antibody persistence after a primary series of a new DTaP-IPV-Hep B-PRP-T combined vaccine or separate DTaP-IPV//PRP-T and hepatitis B vaccines at 2, 4, and 6 months of age and the effect of a subsequent DTaP-IPV//PRP-T booster vaccination at 18 months of age in healthy Argentinean infants.
Tregnaghi M; Zambrano B; Santos-Lima E
Pediatr Infect Dis J; 2012 Jan; 31(1):e24-30. PubMed ID: 22157567
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
